ProKidney Corp. (PROK)
1.83
-0.02
(-1.08%)
USD |
NASDAQ |
Sep 10, 16:00
1.83
0.00 (0.00%)
After-Hours: 20:00
ProKidney Debt to Equity Ratio : -0.004 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.004 |
| March 31, 2026 | -0.0037 |
| December 31, 2025 | -0.004 |
| September 30, 2025 | -0.0042 |
| June 30, 2025 | -0.0044 |
| March 31, 2025 | -0.0034 |
| December 31, 2024 | -0.0033 |
| September 30, 2024 | -0.0066 |
| June 30, 2024 | -0.0069 |
| March 31, 2024 | -0.0054 |
| December 31, 2023 | -0.004 |
| Date | Value |
|---|---|
| September 30, 2023 | -0.0025 |
| June 30, 2023 | -0.0022 |
| March 31, 2023 | -0.0019 |
| December 31, 2022 | -0.0022 |
| September 30, 2022 | -0.002 |
| June 30, 2022 | 0.0011 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.0496 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 15.23 |
| March 31, 2021 | 0.0152 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.012 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 249.02M |
| Total Liabilities (Quarterly) | 26.18M |
| Shareholders Equity (Quarterly) | -883.53M |
| Current Ratio | 8.356 |
| Net Debt Paydown Yield | -0.01% |